



COMPANY RELEASE

4 June 2007

William Gannon Jr., M.D., M.B.A. joins AION Scientific Advisory Board

Perth, Australia – AION Diagnostics Inc, a nano-diagnostics company commercializing medical imaging agents, announced today the appointment of William E. Gannon Jr., M.D., M.B.A., expert in clinical and regulatory affairs, to its Scientific Advisory Board.

Dr Gannon is founder and Chief Medical Officer of Aphera Inc., a company commercializing a peptide-based immunotherapy for the treatment of early-stage Her2-positive breast cancer. Dr. Gannon is an expert in the development, commercialization, marketing and management of health-care products and medical devices. With extensive senior management level experience at two of the worlds largest Regulatory Contract Research Organizations; Quintiles and Pharmaceutical Product Development Inc, Dr. Gannon also holds expertise in the management of regulatory global submissions. This includes experience with FDA processes, European (ISO 9000), Canadian and Japanese regulatory environments as well as IBC AHA and JCAHO affairs. Dr. Gannon is an experienced biopharmaceutical executive, most recently with oncology focused company, Celsion Corporation.

“Dr. Gannon’s regulatory and clinical expertise will further support and accelerate commercialization of AION’s products,” reported Dr. Anna Kluczewska, President and CEO of AION.

The AION Scientific Advisory Board is chartered to provide independent scientific and strategic advice to the Company’s operations.

- ENDS -

Released by:

AION Diagnostics

Alexandra Brown

Ph: +61 (8) 6461 9400

alexandra_brown@aiondiagnostics.com

European Public Relations

Dr. Eva Reuter

Ph: +49 (254) 393 0740

e.reuter@dr-reuter.eu

NOTES TO EDITORS:

AION Diagnostics (AION) is a global biotechnology company dedicated to the commercialization of medical imaging contrast and molecular imaging agents for early stage detection of critical diseases. Founded in 2004, AION secured strategic alliances with universities, research institutions and industry partners internationally.

Exploiting the 10-year history of discoveries of porous silicon made at the former UK Defence Evaluation Agency (now QinetiQ) and backed by USD\$50 million in cumulative previous investment in the technology, AION have developed modified porous silicon (mpSi) which has been proven visible across all major imaging modalities. AION is leveraging the unique visualization capabilities of the mpSi technology platform with its biodegradable and biocompatible properties to produce imaging product divisions in Marking, Contrast and Molecular Imaging Agents. Additionally, one such strategic objective is the development of collaborations incorporating the mpSi platform with other materials to create superior versions of existing products.

Continuing to strive for better solutions to unmet diagnostic needs, AION's products are committed to the timely visualization of pathologies in a manner which may facilitate prevention rather than treatment of disease.

This press release and the information contained therein do not constitute an offer for sale or a solicitation for submission of an offer for purchase or subscription of shares in AION Diagnostics Inc in Germany nor outside Germany, especially in the United States, Canada, Japan or the United Kingdom and Northern Ireland. This press release is provided solely for information purposes.